20% Off Biosimilar Antibodies from AntibodySystem
Boost your research budget with 20% off a wide range of biosimilar antibodies from AntibodySystem!
Terms and Conditions:
- Discounted price is available until March 31st 2025.
- Receive 20% off when purchasing any biosimilar antibodies supplied AntibodySystem from the list of included products below.
- This offer cannot be used in conjunction with any other offers.
- Not applicable for custom products.
- To redeem this offer, or for discounts tailored to academic pricing, please contact our sales team.
| SKU | Product Name |
|---|---|
Research Grade Bermekimab | |
Research Grade Gevokizumab | |
Research Grade Pascolizumab | |
Research Grade Ziltivekimab | |
Research Grade Sirukumab | |
Research Grade Olokizumab | |
Research Grade Clazakizumab | |
Research Grade Enokizumab | |
Research Grade Briakinumab | |
Research Grade Cendakimab | |
Research Grade Lebrikizumab | |
Research Grade Tralokinumab | |
Research Grade Anrukinzumab | |
Research Grade Dectrekumab | |
Research Grade Bimekizumab | |
Research Grade Vunakizumab | |
Research Grade Netakimab | |
Research Grade Perakizumab | |
Research Grade Afasevikumab | |
Research Grade Fletikumab | |
Research Grade Avizakimab | |
Research Grade Fezakinumab | |
Research Grade Brazikumab | |
Research Grade Mirikizumab | |
Research Grade Etokimab | |
Research Grade Itepekimab | |
Research Grade Sifalimumab | |
Research Grade Faralimomab | |
Research Grade Rontalizumab | |
Research Grade Fontolizumab | |
Research Grade Nerelimomab | |
Research Grade Fresolimumab | |
Research Grade Metelimumab | |
Research Grade Lerdelimumab | |
Research Grade Xentuzumab | |
Research Grade Dusigitumab | |
Research Grade Varisacumab | |
Research Grade Tanezumab | |
Research Grade Fasinumab | |
Research Grade Fulranumab | |
Research Grade Frunevetmab | |
Research Grade Ficlatuzumab | |
Research Grade Rilotumumab | |
Research Grade Pamrevlumab | |
Research Grade Lacnotuzumab | |
Research Grade Namilumab | |
Research Grade Otilimab | |
Research Grade Lenzilumab | |
Research Grade Gimsilumab | |
Research Grade Carlumab | |
Research Grade Bertilimumab | |
Research Grade Quetmolimab | |
Research Grade Eldelumab | |
Research Grade Pateclizumab | |
Research Grade Tezepelumab | |
Research Grade Spesolimab | |
Research Grade Siplizumab | |
Research Grade Muromonab | |
Research Grade Otelixizumab | |
Research Grade Teplizumab | |
Research Grade Visilizumab | |
Research Grade Foralumab | |
Research Grade Zanolimumab | |
Research Grade Tregalizumab | |
Research Grade Cedelizumab | |
Research Grade Clenoliximab | |
Research Grade Keliximab | |
Research Grade Zolimomab | |
Research Grade Itolizumab | |
Research Grade Odulimomab | |
Research Grade Atibuclimab | |
Research Grade Erlizumab | |
Research Grade Coltuximab | |
Research Grade Denintuzumab | |
Research Grade Obexelimab | |
Research Grade Ublituximab | |
Research Grade Ripertamab | |
Research Grade Tositumomab | |
Research Grade Veltuzumab | |
Research Grade Ocaratuzumab | |
Research Grade Epratuzumab | |
Research Grade Anti-Human CD22 Antibody (Immurait-Ll2Mab) | |
Research Grade Pinatuzumab | |
Research Grade Lumiliximab | |
Research Grade Inolimomab | |
Research Grade Begelomab | |
Research Grade Varlilumab | |
Research Grade Lulizumab | |
Research Grade Iratumumab | |
Research Grade Lintuzumab | |
Research Grade Vadastuximab | |
Research Grade Naratuximab | |
Research Grade Mezagitamab | |
Research Grade Felzartamab | |
Research Grade Iscalimab | |
Research Grade Bleselumab | |
Research Grade Selicrelumab | |
Research Grade Giloralimab | |
Research Grade Lucatumumab | |
Research Grade Mitazalimab | |
Research Grade Vanalimab | |
Research Grade Dacetuzumab | |
Research Grade Teneliximab | |
Research Grade Ravagalimab | |
Research Grade Tadocizumab | |
Research Grade Bivatuzumab | |
Research Grade Apamistamab | |
Research Grade Urabrelimab | |
Research Grade Vatelizumab | |
Research Grade Etrolizumab | |
Research Grade Abrilumab | |
Research Grade Volociximab | |
Research Grade Abituzumab | |
Research Grade Etaracizumab | |
Research Grade Intetumumab | |
Research Grade Gatralimab | |
Research Grade Bersanlimab | |
Research Grade Enlimomab | |
Research Grade Lorvotuzumab | |
Research Grade Aselizumab | |
Research Grade Inclacumab | |
Research Grade Tinurilimab | |
Research Grade Labetuzumab | |
Research Grade Altumomab | |
Research Grade Cusatuzumab | |
Research Grade Vorsetuzumab | |
Research Grade Oleclumab | |
Research Grade Milatuzumab | |
Research Grade Iladatuzumab | |
Research Grade Galiximab | |
Research Grade Avdoralimab | |
Research Grade Pepinemab | |
Research Grade Carotuximab | |
Research Grade Cabiralizumab | |
Research Grade Emactuzumab | |
Research Grade Axatilimab | |
Research Grade Mavrilimumab | |
Research Grade Talacotuzumab | |
Research Grade Levilimab | |
Research Grade Ivuxolimab | |
Research Grade Pogalizumab | |
Research Grade Tavolimab | |
Research Grade Cudarolimab | |
Research Grade Revdofilimab | |
Research Grade Telazorlimab | |
Research Grade Narnatumab | |
Research Grade Urelumab | |
Research Grade Utomilumab | |
Research Grade Indatuximab | |
Research Grade Tovetumab | |
Research Grade Rinucumab | |
Research Grade Tisotumab | |
Research Grade Imaprelimab | |
Research Grade Meplazumab | |
Research Grade Zalifrelimab | |
Research Grade Tremelimumab | |
Research Grade Ticilimumab | |
Research Grade Nurulimab | |
Research Grade Ruplizumab | |
Research Grade Lirilumab | |
Research Grade Lacutamab | |
Research Grade Monalizumab | |
Research Grade Praluzatamab | |
Research Grade Ulocuplumab | |
Research Grade Plozalizumab | |
Research Grade Leronlimab | |
Research Grade Samalizumab | |
Research Grade Ganitumab | |
Research Grade Cixutumumab | |
Research Grade Figitumumab | |
Research Grade Ieramilimab | |
Research Grade Relatlimab | |
Research Grade Encelimab | |
Research Grade Fianlimab | |
Research Grade Miptenalimab | |
Research Grade Gatipotuzumab | |
Research Grade Sontuzumab | |
Research Grade Clivatuzumab | |
Research Grade Pankomab | |
Research Grade Roledumab | |
Research Grade Ontuxizumab | |
Research Grade Oxelumab | |
Research Grade Tabalumab | |
Research Grade Mapatumumab | |
Research Grade Benufutamab | |
Research Grade Tigatuzumab | |
Research Grade Conatumumab | |
Research Grade Drozitumab | |
Research Grade Lexatumumab | |
Research Grade Tilogotamab | |
Research Grade Enavatuzumab | |
Research Grade Ianalumab | |
Research Grade Tifcemalimab | |
Research Grade Pacmilimab | |
Research Grade Cosibelimab | |
Research Grade Manelimab | |
Research Grade Adebrelimab | |
Research Grade Opucolimab | |
Research Grade Prezalumab | |
Research Grade Enoblituzumab | |
Research Grade Omburtamab | |
Research Grade Mirzotamab | |
Research Grade Vopratelimab | |
Research Grade Feladilimab | |
Research Grade Balstilimab | |
Research Grade Cetrelimab | |
Research Grade Tislelizumab | |
Research Grade Sintilimab | |
Research Grade Toripalimab | |
Research Grade Budigalimab | |
Research Grade Camrelizumab | |
Research Grade Lodapolimab | |
Research Grade Serplulimab | |
Research Grade Spartalizumab | |
Research Grade Prolgolimab | |
Research Grade Retifanlimab | |
Research Grade Sasanlimab | |
Research Grade Ezabenlimab | |
Research Grade Tomaralimab | |
Research Grade Vesencumab | |
Research Grade Olinvacimab | |
Research Grade Vulinacimab | |
Research Grade Tesnatilimab | |
Research Grade Azintuxizumab | |
Research Grade Citatuzumab | |
Research Grade Edrecolomab | |
Research Grade Bemarituzumab | |
Research Grade Aprutumab | |
Research Grade Vofatamab | |
Research Grade Disitamab | |
Research Grade Timigutuzumab | |
Research Grade Tabituximab | |
Research Grade Ragifilimab | |
Research Grade Cobolimab | |
Research Grade Sabatolimab | |
Research Grade Astegolimab | |
Research Grade Nemolizumab | |
Research Grade Anifrolumab | |
Research Grade Modotuximab | |
Research Grade Tomuzotuximab | |
Research Grade Depatuxizumab | |
Research Grade Demupitamab | |
Research Grade Zatuximab | |
Research Grade Laprituximab | |
Research Grade Losatuxizumab | |
Research Grade Nimotuzumab | |
Research Grade Serclutamab | |
Research Grade Zalutumumab | |
Research Grade Ligelizumab | |
Research Grade Talizumab | |
Research Grade Quilizumab | |
Research Grade Sutimlimab | |
Research Grade Olendalizumab | |
Research Grade Tesidolumab | |
Research Grade Crovalimab | |
Research Grade Pozelimab | |
Research Grade Vilobelimab | |
Research Grade Osocimab | |
Research Grade Abelacimab | |
Research Grade Garadacimab | |
Research Grade Befovacimab | |
Research Grade Concizumab | |
Research Grade Marstacimab | |
Research Grade Crenezumab | |
Research Grade Donanemab | |
Research Grade Gantenerumab | |
Research Grade Aducanumab | |
Research Grade Solanezumab | |
Research Grade Lecanemab | |
Research Grade Bapineuzumab | |
Research Grade Ponezumab | |
Research Grade Gosuranemab | |
Research Grade Zagotenemab | |
Research Grade Tilavonemab | |
Research Grade Semorinemab | |
Research Grade Bepranemab | |
Research Grade Cinpanemab | |
Research Grade Prasinezumab | |
Research Grade Tamrintamab | |
Research Grade Girentuximab | |
Research Grade Andecaliximab | |
Research Grade Elgemtumab | |
Research Grade Lumretuzumab | |
Research Grade Duligotuzumab | |
Research Grade Patritumab | |
Research Grade Seribantumab | |
Research Grade Tiragolumab | |
Research Grade Etigilimab | |
Research Grade Frovocimab | |
Research Grade Bococizumab | |
Research Grade Lodelcizumab | |
Research Grade Ralpancizumab | |
Research Grade Tafolecimab | |
Research Grade Ongericimab | |
Research Grade Landogrozumab | |
Research Grade Trevogrumab | |
Research Grade Domagrozumab | |
Research Grade Stamulumab | |
Research Grade Emibetuzumab | |
Research Grade Telisotuzumab | |
Research Grade Timolumab | |
Research Grade Abagovomab | |
Research Grade Oregovomab | |
Research Grade Sofituzumab | |
Research Grade Demcizumab | |
Research Grade Enoticumab | |
Research Grade Farletuzumab | |
Research Grade Mirvetuximab | |
Research Grade Indusatumab | |
Research Grade Orilanolimab | |
Research Grade Rozanolixizumab | |
Research Grade Batoclimab | |
Research Grade Nipocalimab | |
Research Grade Blosozumab | |
Research Grade Setrusumab | |
Research Grade Volagidemab | |
Research Grade Crotedumab | |
Research Grade Anetumab | |
Research Grade Amatuximab | |
Research Grade Ozanezumab | |
Research Grade Atinumab | |
Research Grade Enapotamab | |
Research Grade Tilvestamab | |
Research Grade Rosopatamab | |
Research Grade Dezamizumab | |
Research Grade Elezanumab | |
Research Grade Ensituximab | |
Research Grade Flanvotumab | |
Research Grade Garetosmab | |
Research Grade Glembatumumab | |
Research Grade Icrucumab | |
Research Grade Ifabotuzumab | |
Research Grade Imalumab | |
Research Grade Lifastuzumab | |
Research Grade Upifitamab | |
Research Grade Ladiratuzumab | |
Research Grade Lupartumab | |
Research Grade Murlentamab | |
Research Grade Narsoplimab | |
Research Grade Nesvacumab | |
Research Grade Nadunolimab | |
Research Grade Nimacimab | |
Research Grade Ontamalimab | |
Research Grade Onvatilimab | |
Research Grade Opicinumab | |
Research Grade Parsatuzumab | |
Research Grade Tacatuzumab | |
Research Grade Birtamimab | |
Research Grade Refanezumab | |
Research Grade Rosmantuzumab | |
Research Grade Rolinsatamab | |
Research Grade Rovalpituzumab | |
Research Grade Datopotamab | |
Research Grade Samrotamab | |
Research Grade Sibrotuzumab | |
Research Grade Simtuzumab | |
Research Grade Sirtratumab | |
Research Grade Brontictuzumab | |
Research Grade Tarextumab | |
Research Grade Vandortuzumab | |
Research Grade Vantictumab | |
Research Grade Zampilimab | |
Research Grade Zelminemab | |
Research Grade Zolbetuximab | |
Research Grade Apolizumab | |
Research Grade Ascrinvacumab | |
Research Grade Bimagrumab | |
Research Grade Codrituzumab | |
Research Grade Cofetuzumab | |
Research Grade Satumomab | |
Research Grade Minretumomab | |
Research Grade Orticumab | |
Research Grade Bexmarilimab | |
Research Grade Alsevalimab | |
Research Grade Pritumumab | |
Research Grade Ecromeximab | |
Research Grade Racotumomab | |
Research Grade Bavituximab | |
Research Grade Pagibaximab | |
Research Grade Tosatoxumab | |
Research Grade Suvratoxumab | |
Research Grade Atidortoxumab | |
Research Grade Berlimatoxumab | |
Research Grade Tefibazumab | |
Research Grade Pritoxaximab | |
Research Grade Urtoxazumab | |
Research Grade Setoxaximab | |
Research Grade Cilgavimab | |
Research Grade Bamlanivimab | |
Research Grade Casirivimab | |
Research Grade Imdevimab | |
Research Grade Etesevimab | |
Research Grade Sotrovimab | |
Research Grade Sevirumab | |
Research Grade Regavirumab | |
Research Grade Exbivirumab | |
Research Grade Libivirumab | |
Research Grade Lenvervimab | |
Research Grade Suvizumab | |
Research Grade Elipovimab | |
Research Grade Diridavumab | |
Research Grade Firivumab | |
Research Grade Gedivumab | |
Research Grade Nirsevimab | |
Research Grade Motavizumab | |
Research Grade Suptavumab | |
Research Grade Foravirumab | |
Research Grade Rafivirumab | |
Research Grade Docaravimab | |
Research Grade Miromavimab | |
Research Grade Larcaviximab | |
Research Grade Cosfroviximab | |
Research Grade Anti-Human IL8/CXCL8 Antibody (HuMax-IL8) | |
Research Grade Anti-Human IL8/CXCL8 Antibody (ABX-IL8) | |
Research Grade Anti-Human IL15 Antibody (HuMax-IL15) | |
Research Grade Anti-Human CD185/CXCR5 Antibody (SAR113244) | |
Research Grade Anti-Human CD274/PD-L1/B7-H1 Antibody (BMS-936559/MDX-1105) | |
Research Grade Capromab | |
Research Grade Basiliximab | |
Research Grade Daclizumab | |
Research Grade Palivizumab | |
Research Grade Gemtuzumab | |
Research Grade Alemtuzumab | |
Research Grade Ibritumomab | |
Research Grade Omalizumab | |
Research Grade Bevacizumab | |
Research Grade Natalizumab | |
Research Grade Panitumumab | |
Research Grade Canakinumab | |
Research Grade Golimumab | |
Research Grade Ofatumumab | |
Research Grade Ustekinumab | |
Research Grade Denosumab | |
Research Grade Tocilizumab | |
Research Grade Belimumab | |
Research Grade Brentuximab | |
Research Grade Ipilimumab | |
Research Grade Pertuzumab | |
Research Grade Raxibacumab | |
Research Grade Obinutuzumab | |
Research Grade Ramucirumab | |
Research Grade Siltuximab | |
Research Grade Vedolizumab | |
Research Grade Alirocumab | |
Research Grade Daratumumab | |
Research Grade Dinutuximab | |
Research Grade Elotuzumab | |
Research Grade Evolocumab | |
Research Grade Necitumumab | |
Research Grade Nivolumab | |
Research Grade Secukinumab | |
Research Grade Mepolizumab | |
Research Grade Atezolizumab | |
Research Grade Ixekizumab | |
Research Grade Olaratumab | |
Research Grade Reslizumab | |
Research Grade Benralizumab | |
Research Grade Brodalumab | |
Research Grade Dupilumab | |
Research Grade Durvalumab | |
Research Grade Guselkumab | |
Research Grade Inotuzumab | |
Research Grade Ocrelizumab | |
Research Grade Sarilumab | |
Research Grade Burosumab | |
Research Grade Cemiplimab | |
Research Grade Emapalumab | |
Research Grade Erenumab | |
Research Grade Fremanezumab | |
Research Grade Galcanezumab | |
Research Grade Ibalizumab | |
Research Grade Lanadelumab | |
Research Grade Mogamulizumab | |
Research Grade Ravulizumab | |
Research Grade Polatuzumab | |
Research Grade Risankizumab | |
Research Grade Romosozumab | |
Research Grade Crizanlizumab | |
Research Grade Enfortumab | |
Research Grade Teprotumumab | |
Research Grade Eptinezumab | |
Research Grade Isatuximab | |
Research Grade Sacituzumab | |
Research Grade Inebilizumab | |
Research Grade Belantamab | |
Research Grade Tafasitamab | |
Research Grade Satralizumab | |
Research Grade Atoltivimab | |
Research Grade Maftivimab | |
Research Grade Odesivimab | |
Research Grade Naxitamab | |
Research Grade Margetuximab | |
Research Grade Ansuvimab | |
Research Grade Evinacumab | |
Research Grade Dostarlimab | |
Research Grade Loncastuximab | |
Research Grade Pelgifatamab | |
Research Grade Amlitelimab | |
Research Grade Garivulimab | |
Research Grade Sudubrilimab | |
Research Grade Alomfilimab | |
Research Grade Coprelotamab | |
Research Grade Bapotulimab | |
Research Grade Barecetamab | |
Research Grade Botensilimab | |
Research Grade Finotonlimab | |
Research Grade Geptanolimab | |
Research Grade Penpulimab | |
Research Grade Pimivalimab | |
Research Grade Dafsolimab | |
Research Grade Daxdilimab | |
Research Grade Depemokimab | |
Research Grade Divozilimab | |
Research Grade Zuberitamab | |
Research Grade Domvanalimab | |
Research Grade Ociperlimab | |
Research Grade Ebdarokimab | |
Research Grade Ebronucimab | |
Research Grade Torudokimab | |
Research Grade Tozorakimab | |
Research Grade Enibarcimab | |
Research Grade Grisnilimab | |
Research Grade Idactamab | |
Research Grade Imsidolimab | |
Research Grade Latozinemab | |
Research Grade Lemzoparlimab | |
Research Grade Letaplimab | |
Research Grade Lusvertikimab | |
Research Grade Melrilimab | |
Research Grade Mibavademab | |
Research Grade Nadecnemab | |
Research Grade Omodenbamab | |
Research Grade Plonmarlimab | |
Research Grade Ponsegromab | |
Research Grade Sibeprenlimab | |
Research Grade Sotigalimab | |
Research Grade Surzebiclimab | |
Research Grade Tixagevimab | |
Research Grade Tusamitamab | |
Research Grade Uliledlimab | |
Research Grade Vixarelimab | |
Research Grade Zansecimab | |
Research Grade Zilovertamab | |
Research Grade Anti-Human CD22 (M971) | |
Research Grade Anti-Human CD22 (M972) | |
Research Grade Dresbuxelimab | |
Research Grade Mupadolimab | |
Research Grade Nofazinlimab | |
Research Grade Iparomlimab | |
Research Grade Gumokimab | |
Research Grade Tamgiblimab | |
Research Grade Pivekimab | |
Research Grade Ginisortamab | |
Research Grade Galegenimab | |
Research Grade Ivicentamab | |
Research Grade Anselamimab | |
Research Grade Anumigilimab | |
Research Grade Sirexatamab | |
Research Grade Rocatinlimab | |
Research Grade Ligufalimab | |
Research Grade Manfidokimab | |
Research Grade Trinbelimab | |
Research Grade Barzolvolimab | |
Research Grade Eblasakimab | |
Research Grade Mazorelvimab | |
Research Grade Zamerovimab | |
Research Grade Amubarvimab | |
Research Grade Romlusevimab | |
Research Grade Adintrevimab | |
Research Grade Anti-SARS-CoV-2 RBD Antibody(S2H97) | |
Research Grade Anti-SARS-CoV-2 RBD Antibody (S2E12) | |
Research Grade Bebtelovimab | |
Research Grade Anti-Human CD115/CSF1R Antibody (LY3022855) | |
Research Grade Ispectamab | |
Research Grade Ifinatamab | |
Research Grade Vobramitamab | |
Research Grade Peresolimab | |
Research Grade Rosnilimab | |
Research Grade Zimberelimab | |
Research Grade Anivovetmab | |
Research Grade Briquilimab | |
Research Grade Camoteskimab | |
Research Grade Frexalimab | |
Research Grade Golocdacimab | |
Research Grade Litifilimab | |
Research Grade Zinlirvimab | |
Research Grade Ozuriftamab | |
Research Grade Posdinemab | |
Research Grade Visugromab | |
Research Grade Apitegromab | |
Research Grade Theralizumab | |
Research Grade Anti-Human CD47/MER6 Antibody (CC-90002) | |
Research Grade Anti-Human SIRPα / γ Antibody (Kwar23) | |
Research Grade Anti-Human DKK1 Antibody (BHQ880) | |
Research Grade Anti-Human CD85d/ILT4 Antibody (JTX-8064-101) | |
Research Grade Anti-Human CD112R/PVRIG (GSK4381562) | |
Research Grade Anti-Human IL10 Antibody (BT-063) | |
Research Grade Anti-Human IL11RA Antibody (X209) | |
Research Grade Anti-Human CDH6 Antibody (HKT288) | |
Research Grade Fanolesomab | |
Research Grade Anti-Human TPBG/5T4 (PF-06263507) | |
Research Grade Anti-Human GPA33 (KRN330) | |
Research Grade Anti-Human ADAM9 (IMGC936) | |
Research Grade Anti-Human CD166/ALCAM (AT002) | |
Research Grade Anti-Human APP/Amyloid beta (CNTO 2125) | |
Research Grade Anti-Human APP/Amyloid beta (DLX212) | |
Research Grade Anti-Human APP/Amyloid beta (GSK 933776) | |
Research Grade Anti-Human ANGPT2 (MEDI-3617) | |
Research Grade Anti-Human AXL/UFO (ORY012) | |
Research Grade Anti-Human CD276/B7-H3 (DS-5573a) | |
Research Grade Anti-Human CD317/BST2 (XmAb 5592) | |
Research Grade Anti-Human CD272/BTLA (LY3361237) | |
Research Grade Anti-Human CNR1/CB1 (GFB-024) | |
Research Grade Anti-Human CCL20/MIP-3-alpha (GSK3050002) | |
Research Grade Anti-Human CD163 (OR2805) | |
Research Grade Anti-Human CD20/MS4A1 (TRU015) | |
Research Grade Anti-Human CD28 (FR-104) | |
Research Grade Anti-Human CD33 (IMGN779) | |
Research Grade Anti-Human CD37/TSPAN26 (AGS67E) | |
Research Grade Anti-Human CD39/ENTPD1 (TTX-030) | |
Research Grade Anti-Human CD39/ENTPD1 (SRF617) | |
Research Grade Anti-Human CD4 (TRX1) | |
Research Grade Anti-Human CD98/SLC3A2 (IGN523) | |
Research Grade Anti-Human CDH6 (DS-6000a) | |
Research Grade Anti-Human CD66c/CEACAM6 (NEO-201) | |
Research Grade Anti-Human CLDN6 (IMAB-027) | |
Research Grade Anti-Human MET/c-Met/HGFR (REGN5093) | |
Research Grade Anti-Human MET/c-Met/HGFR (SAIT301) | |
Research Grade Anti-Human CXCL10/IP-10 (NI-0801) | |
Research Grade Anti-Human CD205/LY75/DEC-205 (CDX-1401) | |
Research Grade Anti-Human CD205/LY75/DEC-205 (MEN1309) | |
Research Grade Anti-Human DLK1 (ADCT-701) | |
Research Grade Anti-Human CD262/TNFRSF10B/TRAIL-R2/DR5 (DS-8273a) | |
Research Grade Anti-Human EGFR/ERBB1/HER1 (7A7) | |
Research Grade Anti-Human EPHA2 (MEDI-547) | |
Research Grade Anti-Human EPHA4 (PF-06647263) | |
Research Grade Anti-Human CD32/FCGR2A (VIB9600) | |
Research Grade Anti-Human FPN1/SLC40A1/Ferroportin (LY2928057) | |
Research Grade Anti-Human FGF19 (1A6) | |
Research Grade Anti-Human FGF2/bFGF (HuGAL-F2) | |
Research Grade Anti-Human CD333/FGFR3 (LY3076226) | |
Research Grade Anti-Human CD135/FLT3 (IMC-EB10) | |
Research Grade Anti-Human FLT4 (LY3022856) | |
Research Grade Anti-RSV F/Fusion glycoprotein F0 (hRSV90) | |
Research Grade Infliximab | |
Research Grade Adalimumab | |
Research Grade Becotatug | |
Research Grade Bempikibart | |
Research Grade Delpacibart | |
Research Grade Izeltabart | |
Research Grade Perenostobart | |
Research Grade Tulisokibart | |
Research Grade Ulviprubart | |
Research Grade Favezelimab | |
Research Grade Trastuzumab | |
Research Grade Efalizumab | |
Research Grade Camidanlumab | |
Research Grade Magrolimab | |
Research Grade Quavonlimab | |
Research Grade Dalotuzumab | |
Research Grade Robatumumab | |
Research Grade Adecatumumab | |
Research Grade Matuzumab | |
Research Grade Vibostolimab | |
Research Grade Lorukafusp Alfa | |
Research Grade Mitumomab | |
Research Grade Actoxumab | |
Research Grade Anti-Human KLB/Beta-klotho Antibody (MK-3655) | |
Research Grade Lonigutamab | |
Research Grade Cetuximab | |
Research Grade Pembrolizumab | |
Research Grade Avelumab | |
Research Grade Tildrakizumab | |
Research Grade Clesrovimab | |
Research Grade Anti-Human CD66a/CEACAM1 (CM-24) | |
Research Grade Anti-Human IL18/IL1F4 (ABT-325) | |
Research Grade Anti-Human IL15 (DISC0280) | |
Research Grade Teropavimab | |
Research Grade Anti-Human CD334/FGFR4 (U3-1784) | |
Research Grade Ichorcumab | |
Research Grade Lirentelimab | |
Research Grade Leukotuximab | |
Research Grade Neihulizumab | |
Research Grade Arevirumab-3 | |
Research Grade Anti-SARS-CoV-2 S2 Protein (CV3-25) | |
Research Grade Anti-Human GFRAL (NGM120) | |
Research Grade Anti-Human SLC2A8GLUT8 (VB1-050) | |
Research Grade Anti-Human GPR20 (DS-6157a) | |
Research Grade Anti-Human HBEGF (KHK2866) | |
Research Grade Anti-Human HJV/Hemojuvelin (DISC-0974) | |
Research Grade Anti-Human HAMP/Hepcidin (LY2787106) | |
Research Grade Anti-Human HGF (TAK-701) | |
Research Grade Anti-Human HLA-DR (IMMU-114) | |
Research Grade Anti-Human CD278/ICOS (MEDI-570) | |
Research Grade Anti-Human IFNG/IFN-gamma (AMG 811) | |
Research Grade Anti-Human IGF2 (DX-2647) | |
Research Grade Anti-Human IL13 (H2L6) | |
Research Grade Anti-Human IL13 (M1295) | |
Research Grade Anti-Human IL13 (CNTO 607) | |
Research Grade Anti-Human IL13 (GSK679586) | |
Research Grade Anti-Human IL13 (IMA-026) | |
Research Grade Anti-Human IL17A (CAT-2200) | |
Research Grade Anti-Human IL18/IL1F4 (GSK 1070806) | |
Research Grade Anti-Human IL1B/IL1F2 (CDP484) | |
Research Grade Anti-Human IL23A/IL-23p19 (LY2525623) | |
Research Grade Anti-Human CD123/IL3RA (SGN-CD123A) | |
Research Grade Anti-Human CD124/IL4R/IL-4Rα (MEDI2045) | |
Research Grade Anti-Human ITGB6 (SGN-B6A) | |
Research Grade Anti-Human KAAG1 (ADCT-901) | |
Research Grade Anti-Human CD117/KIT (LOP628) | |
Research Grade Anti-Human CD107a/LAMP1 (SAR428926) | |
Research Grade Anti-Human LGR5 (BNC101) | |
Research Grade Anti-Human LIF (MSC-1) | |
Research Grade Anti-LPA/Lysophosphatidic acid Antibody (LT3015) | |
Research Grade Anti-Human MSLN/Mesothelin (BMS 986148) | |
Research Grade Anti-Human NGF/Beta-NGF (AS2886401-00) | |
Research Grade Anti-Human NGF/Beta-NGF (MEDI-578) | |
Research Grade Anti-Human OPN/SPP1 (ASK8007) | |
Research Grade Anti-Human CD134/TNFRSF4/OX40 (BMS 986178) | |
Research Grade Anti-Human CDH3/P-cadherin (PF-03732010) | |
Research Grade Anti-Human PCSK9 (RG7652) | |
Research Grade Anti-Human PDGFB (MOR-8457) | |
Research Grade Anti-Human CD140b/PDGFRB (IMC-2C5) | |
Research Grade Anti-Human PRLR (BAY 1158061) | |
Research Grade Anti-Human CCL5/RANTES (NI-0701) | |
Research Grade Anti-Human S100A4 (LK-1) | |
Research Grade Anti-Human SIGLEC15/CD33L3 (AB-25E9) | |
Research Grade Anti-Human SIGLEC15/CD33L3 (NC318) | |
Research Grade Anti-Human CD319/SLAMF7 (PDL241) | |
Research Grade Anti-Human MAPT/Tau/PHF-tau (APNmAb005) | |
Research Grade Anti-Human CD142/F3/TF (TNX-832) | |
Research Grade Anti-Human TGFB1/TGF-beta-1 (SRK-181) | |
Research Grade Anti-Human CD283/TLR3 (CNTO5429) | |
Research Grade Anti-Human TNFa/TNF-alpha (ESBA 105) | |
Research Grade Anti-Human TNFa/TNF-alpha (CMAB008) | |
Research Grade Anti-Human CD354/TREM1 (PY159) | |
Research Grade Anti-Human VEGFB (CSL 346) | |
Research Grade Anti-Human VEGFC (VGX100) | |
Research Grade Anti-Human CD309/KDR/VEGFR-2 (ImClone 6.64) | |
Research Grade Anti-Human Lewis Y (MB 311) | |
Research Grade Anti-Human NTRK1/TRKA (GBR 900) | |
Research Grade Sonepcizumab | |
Research Grade Anti-SARS-CoV-2 RBD Antibody (BD55-5514) | |
Research Grade Anti-Human TERM2 Antibody (PY314) | |
Research Grade Vopikitug | |
Research Grade Davutamig | |
Research Grade Duvakitug | |
Research Grade Enlonstobart | |
Research Grade Ersodetug | |
Research Grade Gotistobart | |
Research Grade Maridebart | |
Research Grade Oberotatug | |
Research Grade Oloctinebart | |
Research Grade Patecibart | |
Research Grade Rademikibart | |
Research Grade Stapokibart | |
Research Grade Sabirnetug | |
Research Grade Temtokibart | |
Research Grade Verzistobart | |
Research Grade Anti-Human CD272/BTLA Antibody (22B3) | |
Research Grade Anti-Human IL22RA1 Antibody (ARGX-112) | |
Research Grade Anti-Human SEZ6 Antibody (ABBV-011) | |
Research Grade Rituximab | |
Research Grade Abiprubart | |
Research Grade Rezorstobart | |
Research Grade Seniprutug | |
Research Grade Sigvotatug | |
Research Grade Sipavibart | |
Research Grade Solrikitug | |
Research Grade Ucenprubart | |
Research Grade Venanprubart | |
Research Grade Verekitug | |
Research Grade Atrosimab | |
Research Grade Anti-HBsAg Reference Antibody (OST 577) | |
Research Grade Amlenetug | |
Research Grade Bosakitug | |
Research Grade Misitatug | |
Research Grade Ruxoprubart | |
Research Grade Anti-Human Fucosyl-GM1 Antibody (BMS-986012) | |
Research Grade Anti-Human ACVR1/ALK-2 Antibody (DS-6016a) | |
Research Grade Anti-Human ACVR2A Antibody (Ab-14E1) | |
Research Grade Anti-Human KLB/Beta-klotho Antibody (RG7992) | |
Research Grade Anti-Human CTSS/Cathepsin S Antibody (Fsn0503h) | |
Research Grade Anti-Human CCL5/RANTES Antibody (VLST-002) | |
Research Grade Anti-Human CD46 Antibody (FOR46) | |
Research Grade Anti-Human DCBLD2CLCP1 Antibody (FA19-1) | |
Research Grade Anti-Human Fibronectin Antibody (L19-TNF) | |
Research Grade Anti-Human LAP (TGFB3) Antibody (Brigham and Womens anti-LAP) | |
Research Grade Anti-Human MERTK/MER Antibody (RGX-019) | |
Research Grade Anti-Human TYRO3/DTK/SYK Antibody (ELB031) | |
Research Grade Anti-Human CD228/MELTF Antibody (SC-005) | |
Research Grade Anti-Human Complement C2 Antibody (ARGX-117) | |
Research Grade Anti-Human Complement C3 Antibody (NGM621) | |
Research Grade Anti-Human CLU/APOJ/Clusterin Antibody (AB-16B5) | |
Research Grade Anti-Human CD29/ITGB1 Antibody (OS2966) | |
Research Grade Anti-ChoPPhosphorylcholine Antibody (ATH3G10) | |
Research Grade Anti-Human CD213a1/IL13RA1 Antibody (MK-6105) | |
Research Grade Anti-Human CD110/MPL Antibody (TA136) | |
Research Grade Anti-Human SCN9A/Nav1.7 Antibody (Duke anti-NAv1.7) | |
Research Grade Anti-Human RG1/Mindin Antibody (19G9) | |
Research Grade Anti-Human DLK1 Antibody (LIV-1205) | |
Research Grade Anti-Human CD315/PTGFRN Antibody (AG02-ADC) | |
Research Grade Anti-Human EDNRB/ETRB Antibody (DEDN6526A) | |
Research Grade Anti-Human CD117/KIT Antibody (CDX-0158) | |
Research Grade Anti-Human KLK2 Antibody (JNJ-69086420) | |
Research Grade Anti-Human MICA Antibody (CLN-619) | |
Research Grade Anti-Human F2RL1/PAR-2 Antibody (PAR650097) | |
Research Grade Anti-Human CDH11 Antibody (RG6125) | |
Research Grade Anti-Human CD136/MST1R Antibody (Aveo anti-RON) | |
Research Grade Anti-Human BACE1 Antibody (Genentech anti-BACE1) | |
Research Grade Anti-Human PCSK9 Antibody (Boehringer anti-PCSK9) | |
Research Grade Anti-Human CD40/TNFRSF5 Antibody (Emory U. anti-CD40) | |
Research Grade Anti-Human CXCL12/SDF-1 Antibody (Genentech anti-CXCL12) | |
Research Grade Anti-Human EGFR/ERBB1/HER1 Antibody (Duke D2C7) | |
Research Grade Anti-Human CD19 Antibody (Immunomedics hA19) | |
Research Grade Anti-Human CD167a/DDR1 Antibody (Imperial College anti-DDR1) | |
Research Grade Anti-Human HAMP/Hepcidin Antibody (Ludwig-Maximilians U. anti_Hepsin) | |
Research Grade Anti-Human APP/Amyloid beta Antibody (Merck anti-Amyloid beta 19.3) | |
Research Grade Anti-Human IL6/IFNb2 Antibody (MEDI 5117) | |
Research Grade Anti-Human CD126/IL6R/IL-6RA Antibody (APX007) | |
Research Grade Anti-Human CD127/IL7R Antibody (PF-06342674) | |
Research Grade Anti-Human CD255/TNFSF12/TWEAK Antibody (RO5458640/RG7212) | |
Research Grade Anti-Human CD240D/RHD Antibody (LFB Anti-RhD) | |
Research Grade Anti-Human Reticulon-4/RTN4 Antibody (NG-101) | |
Research Grade Anti-Human TGFBR2/TGFR-2 Antibody (LY3022859) | |
Research Grade Anti-Human TCR Antibody (NKTT320) | |
Research Grade Anti-Human TGFB1/TGF-beta-1 Antibody (NIS793) | |
Research Grade Anti-Human TCR Antibody (TOL101) | |
Research Grade Anti-Human TNFa/TNF-alpha Antibody (hMAK195) | |
Research Grade Anti-Human CD309/KDR/VEGFR-2 Antibody (AT001) | |
Research Grade Anti-Human A2AR/ADORA2A Antibody (3F6-9G5) | |
Research Grade Anti-Human BTN1A1 Antibody (ICT-01) | |
Research Grade Anti-Human CD172a/SIRPA Antibody (BI 765063) | |
Research Grade Anti-Human CDH17/Cadherin-17 Antibody (PTA001_A4) | |
Research Grade Anti-Human CLDN6 Antibody (DS-9606a) | |
Research Grade Anti-Human CLDN6 Antibody (AE3-20) | |
Research Grade Anti-Human CLDN6 Antibody (64A) | |
Research Grade Anti-Human CLDN6 Antibody (AB1-11) | |
Research Grade Anti-Human CD136/MST1R Antibody (H5B14) | |
Research Grade Anti-Human CD318/CDCP1 Antibody (38 E11#) | |
Research Grade Anti-Human CD93/C1qR Antibody (Dcby02) | |
Research Grade Anti-Human NAMPT Antibody (Alt-100) | |
Research Grade Anti-Human IL11RA Antibody (LASN 01) | |
Research Grade Lpathomab | |
Research Grade Sphingomab |
